

# James Hardie Former Subsidiaries (Winding up and Administration) Regulation 2007

[2007-44]



New South Wales

## Status Information

### Currency of version

Current version for 23 March 2012 to date (accessed 19 May 2024 at 18:53)

Legislation on this site is usually updated within 3 working days after a change to the legislation.

### Provisions in force

The provisions displayed in this version of the legislation have all commenced.

### Authorisation

This version of the legislation is compiled and maintained in a database of legislation by the Parliamentary Counsel's Office and published on the NSW legislation website, and is certified as the form of that legislation that is correct under section 45C of the [Interpretation Act 1987](#).

File last modified 23 March 2012

# James Hardie Former Subsidiaries (Winding up and Administration) Regulation 2007



New South Wales

## Contents

1 Name of Regulation .....	3
2 Commencement .....	3
3 Definition .....	3
4 Payment of statutory recovery claims during periods of insufficient funding .....	3
5 Prescribed asbestos medical research provider: clause 11 (b) of Schedule 1.....	5
6 James Hardie Industries SE is prescribed continuation of James Hardie Industries NV .....	5

# James Hardie Former Subsidiaries (Winding up and Administration) Regulation 2007



New South Wales

## 1 Name of Regulation

This Regulation is the *James Hardie Former Subsidiaries (Winding up and Administration) Regulation 2007*.

## 2 Commencement

This Regulation commences on 8 February 2007.

## 3 Definition

In this Regulation:

**the Act** means the *James Hardie Former Subsidiaries (Winding up and Administration) Act 2005*.

## 4 Payment of statutory recovery claims during periods of insufficient funding

- (1) For the purposes of section 32 (3) (b) of the Act, statutory recovery claims against a liable entity are to be paid in accordance with the provisions of this clause if the funding (the **available annual funding**) set aside under the Final Funding Agreement for the payment of such claims by the SPF trustee during a financial year beginning with the financial year commencing on 1 April 2012 will not be sufficient to cover the payment of all such claims (whether actual or anticipated) within the year concerned.

### Note—

This clause does not apply to limit the payment of statutory recovery claims if the available annual funding is sufficient to meet all existing and new claims during the financial year concerned.

- (2) Subject to subclauses (3), (4) and (5), the payment of statutory recovery claims from the available annual funding is to be deferred until the period of 7 days before the end of the financial year concerned (the **distribution period**).
- (3) If the available annual funding is sufficient to pay all new claims in full but not all existing claims, then:
  - (a) all new claims are to be paid in full during the distribution period in priority over

any existing claims, and

- (b) any funding that remains from the available annual funding following the payment of all new claims is to be applied during the distribution period:
    - (i) to pay in full as many existing claims as is possible from the remaining funding (commencing with the earliest existing claim the payment of which remains outstanding), and
    - (ii) to pay in part one other existing claim with any funding that remains following the full payment of existing claims in accordance with subparagraph (i), and
  - (c) the payment of the whole or any part of an existing claim that remains outstanding is deferred until the next financial year at which partial or full payment of the claim is permitted by or under the Act.
- (4) If the available annual funding is insufficient to pay all new claims in full and there is only one claimant, then:
- (a) the funding is to be applied during the distribution period:
    - (i) to pay in full as many new claims as is possible from that funding, and
    - (ii) to pay in part one other of the new claims with any funding that remains following the full payment of new claims in accordance with subparagraph (i), and
  - (b) the payment of the whole or any part of a new claim that remains outstanding is deferred until the next financial year at which partial or full payment of the claim is permitted by or under the Act, and
  - (c) the payment of the whole or any part of an existing claim that remains outstanding is deferred until the next financial year at which partial or full payment of the claim is permitted by or under the Act.
- (5) If the available annual funding is insufficient to pay all new claims in full and there is more than one claimant, then:
- (a) the available annual funding is to be allocated between each claimant (a **claimant's allocation**) by reference to the value in total of new claims made by the claimant as a proportion of the value in total of new claims made by all claimants, and
  - (b) each claimant's allocation is to be applied during the distribution period:
    - (i) to pay in full as many of the claimant's new claims as is possible from that allocation, and
    - (ii) to pay in part one other of the claimant's new claims with any funding that

remains following the full payment of new claims in accordance with subparagraph (i), and

- (c) the payment of the whole or any part of a new claim that remains outstanding is deferred until the next financial year at which partial or full payment of the claim is permitted by or under the Act, and
- (d) the payment of the whole or any part of an existing claim that remains outstanding is deferred until the next financial year at which partial or full payment of the claim is permitted by or under the Act.

(6) In this clause:

**existing claim** means any statutory recovery claim made in a previous financial year that remains unpaid (whether wholly or partly).

**new claim** means any statutory recovery claim made in the financial year concerned.

#### **5 Prescribed asbestos medical research provider: clause 11 (b) of Schedule 1**

For the purposes of clause 11 (b) of Schedule 1 to the Act:

- (a) The Asbestos Diseases Research Foundation (ACN 121 168 867) is prescribed as the asbestos medical research provider to which the balance of any trust assets are to be transferred, and
- (b) 100 per cent is prescribed as the proportion of the balance of any trust assets to be transferred to that provider.

#### **6 James Hardie Industries SE is prescribed continuation of James Hardie Industries NV**

The Societas Europaea with the corporate name James Hardie Industries SE (and registered as a foreign company under the Corporations Act with that name and ARBN 097 829 895) is prescribed as a continuation of James Hardie Industries NV for the purposes of the definition of **James Hardie Industries NV** in section 4 (1) of the Act.